Oral low molecular weight heparin absorption: From solution and solid dosage forms in rat, dog, and monkey models

Pharmaceutical Technology

Volumn 26, Issue 3, 2002, Pages 38-46

  Leone Bay, Andrea ^a   O'Shaughnessy, Catherina ^a   Agarwal, Rajesh ^a   Rivera Schaub, Theresa ^a   Rosado Gray, Connie ^a   Gerspach, Linda ^a   Baughman, Robert A ^a  

^a Emisphere Technologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABSORPTION; CELLS; MOLECULAR WEIGHT; PREVENTION; SURGERY; TRANSPLANTATION (SURGICAL);

ORAL DOSE;

DRUG DOSAGE;

DECANOIC ACID DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; OCTANOIC ACID DERIVATIVE; PARNAPARIN; SODIUM 10 [N (2 HYDROXYBENZOYL)AMINO]DECANOATE; SODIUM 8 [N (2 HYDROXYBENZOYL)AMINO]CAPRYLATE; UNCLASSIFIED DRUG;

ABDOMINAL SURGERY; ANIMAL CELL; ANIMAL EXPERIMENT; CELL STRAIN CACO 2; DEEP VEIN THROMBOSIS; DOG; DRUG ABSORPTION; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUTION; FEMALE; JOINT PROSTHESIS; JOINT SURGERY; MALE; MONKEY; NONHUMAN; POSTOPERATIVE COMPLICATION; RAT; REVIEW; SOLID; THROMBOSIS PREVENTION;

EID: 0036200442     PISSN: 01478087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Preoperative versus postoperative initiation of low molecular weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement
2. Subcutaneous low molecular weight heparin or oral anticoagulants for the prevention of deep vein thrombosis in elective hip and knee replacement?
3. Investigation on plasma activity of low molecular weight heparin after intravenous administrations
4. Oral administration of low molecular weight heparin fractions in rabbits
5. Intraduodenal absorption in rabbit of a novel heparin salt
6. Use and characteristics of a novel lipid particle-forming matrix as a drug-carrier system
7. Oral treatment with low molecular weight heparin normalizes blood pressure in hypertensive rats
8. Investigation on plasma activity of low molecular weight heparin after intravenous and oral administrations
9. Synthesis and evaluation of compounds that facilitate the gastrointestinal absorption of heparin
10. Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate - Pharmacological considerations
11. Oral delivery of anticoagulant doses of heparin - A randomized, double-blind, controlled study in humans
12. Orally administered heparin for preventing deep venous thrombosis
13. Orally administered unfractionated heparin with carrier is therapeutic for deep venous thrombosis
14. Epithelial transport of drugs in cell culture: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells
15. N-trimethyl chitosan chloride as a potential absorption enhancer across mucosal surfaces: In vitro evaluation in intestinal epithelial cells (Caco-2)
16. Intestinal permeability enhancement: Efficacy, acute local toxicity, and reversibility
17. Effectiveness and toxicity screening of various absorption enhancers using Caco-2 cell monolayers
18. Absorption enhancement, structural changes in tight junctions and cytotoxicity caused by palmitoyl carnitine in Caco-2 and IEC-18 cells
19. Carrier-mediated human growth hormone absorption across isolated rabbit intestinal tissue
20. A simple method of correlating pharmacodynamic equivalence with absolute bioavailability following non-invasive delivery of insulin